Biocon Pharma's Generic Liraglutide Injection gVictoza Gets US FDA Approval
Loading more articles...
Biocon Pharma secures US FDA nod for generic Liraglutide (gVictoza) injection
C
CNBC TV18•12-03-2026, 23:24
Biocon Pharma secures US FDA nod for generic Liraglutide (gVictoza) injection
•Biocon Pharma, a Biocon subsidiary, secured US FDA approval for its Abbreviated New Drug Application (ANDA) for Liraglutide Injection (gVictoza), 18 mg/3 mL.
•Liraglutide is indicated for treating insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents, and children aged 10 years and above.
•This approval follows the US FDA’s earlier clearance for Liraglutide injection (gSaxenda), further expanding Biocon's portfolio of complex drug products.
•Biocon recently completed the acquisition of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) of its wholly owned subsidiaries, Biocon Biosphere and Biocon Pharma.
•The acquisitions, totaling ₹315.34 crore, ensure Biocon holds 100% of both subsidiaries, supporting their ongoing business requirements including working capital and capex.
